Completed PHASE2 INTERVENTIONAL 2-arm NCT00968045

Fibrinogen and Bleeding After Cardiac Surgery (Fibro-3)

Sponsor: Sahlgrenska University Hospital

Conditions Bleeding Complications Coronary Artery Disease

Interventions Fibrinogen

Updated 7 times since 2017 Last updated: May 19, 2015 Started: Apr 30, 2009 Primary completion: Feb 29, 2012 Completion: May 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00968045, this PHASE2 trial focuses on Bleeding and Complications and remains completed. Sponsored by Sahlgrenska University Hospital, it has been updated 7 times since 2009, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

7 versions recorded

Mar 2025 — Present [monthly]

Completed PHASE2
Feb 2025 — Mar 2025 [monthly]

Completed PHASE2
Sep 2024 — Feb 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sahlgrenska University Hospital

Data source: Sahlgrenska University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Gothenburg, Sweden